Yarrow Bioscience files amended 8-K with Pre-Merger Yarrow financials after VYNE merger

Yarrow Bioscience, Inc., the Delaware company that changed its name from VYNE Therapeutics Inc., filed an amendment to its Form 8-K originally submitted on July 28, 2026, which had disclosed the closing of its merger with the company now called Yarrow Bioscience Operating Company Corp. The merger closed on July 27, 2026.¹

The amendment adds several sets of financial materials. It includes financial statements of Pre-Merger Yarrow as of and for the three and six months ended June 30, 2026, financial statements as of December 31, 2025 and October 3, 2025, and for the period from October 3, 2025 (inception) to December 31, 2025, recast to reflect a 0.7171 exchange ratio applied in the merger, along with related management's discussion and analysis and unaudited pro forma condensed combined financial statements covering the six months ended June 30, 2026 and the year ended December 31, 2025.¹

On the results side, the company issued a press release on August 13, 2026 announcing its financial results for the quarter ended June 30, 2026.¹ That release is furnished as Exhibit 99.7. The same day, Yarrow posted an updated corporate presentation on its website,¹ furnished as Exhibit 99.8.

The filing states that this amendment is limited in scope: it adds the financial exhibits and does not update investors on any company developments, including at Pre-Merger Yarrow, that occurred after the original report's filing date. The prior report's contents remain incorporated by reference.

The 8-K/A itself does not disclose specific trial results, regulatory actions, or a cash runway statement; those details, if present, would appear in the referenced Exhibits 99.5 (MD&A) and 99.7 (earnings release), which are not included in the text provided here.